Radiopharm Theranostics’ Phase 1 HEAT trial cleared its second safety gate, with the independent monitoring committee recommending dose escalation of 177Lu-RAD202 to 130 mCi in patients with HER2-positive advanced solid tumors. The program previously advanced through a 75 mCi cohort, and the company maintains guidance to complete dose escalation by year-end 2026.
The core development is straightforward: based on reviewed safety data, the Data Safety and Monitoring Committee has endorsed moving HEAT into a higher-dose cohort at Australian sites. The agent, a lutetium-177–labeled single-domain antibody targeting HER2, follows a diagnostics-led lineage; a prior small imaging study in HER2-positive breast cancer established biodistribution and safety. The Phase 1 escalation is designed to define a recommended dose and generate initial antitumor activity signals across HER2-expressing solid tumors, a field increasingly managed by antibody-drug conjugates and TKIs but still seeking options post-progression and in heterogeneous or low-expressing disease.
Strategically, the move signals that RAD202’s tolerability window is widening in line with internal timelines, an essential prerequisite for competitive positioning in radioligand therapy where therapeutic index and operability hinge on marrow and renal safety. Radiopharm is pursuing a platform strategy across multiple targets, but HER2 offers a large, multi-indication addressable population if the company can demonstrate response in patients already exposed to modern HER2 regimens. The choice of a single-domain antibody may be intended to improve tumor penetration and clearance dynamics relative to full-length antibodies, potentially sharpening tumor-to-background ratios, though it also places a premium on careful kidney dosimetry. Clearing escalation to 130 mCi suggests those risks remain manageable so far, but the efficacy payoff at higher exposure remains to be seen.
For sites, the update reinforces a steady ramp in radiopharmaceutical trial activity that favors institutions with nuclear medicine capacity, on-site dosimetry, and radiolabeling workflows. Australian centers continue to be used as first-in-human launch pads for radiotheranostics given predictable startup pathways and operational expertise, but scale-out beyond early escalation will test isotope supply chains, labeling logistics, and staffing for radiation safety—areas where many oncology sites are still capacity constrained. CROs with radiopharm-specific monitoring and dosimetry analytics will be central as sponsors push beyond single-center models. Regulators will watch renal and hematologic safety summaries closely and will expect a clear imaging-driven selection framework if Radiopharm intends to pursue a theranostic path to registration. For patients, the most immediate impact is access to a next-generation HER2-directed radioligand in a setting where ADC resistance is common and radiotherapy can exploit target expression independent of canonical resistance mechanisms.
The key next step is determining a recommended Phase 2 dose with credible activity signals across tumor types and HER2 expression levels, alongside a patient-selection strategy that translates prior imaging proof-of-concept into operational screening criteria. Watch for dosimetry outputs at the 130 mCi level, any early objective responses, and evidence of manageable cumulative toxicity with repeat dosing. Commercial viability will hinge on supply of lutetium-177, radiochemistry standardization across regions, and the ability to run multi-regional trials beyond Australia, likely requiring a U.S. IND and broader site network. The competitive risk is clear: HER2 remains crowded and ADCs set a high efficacy bar. RAD202 will need to show differentiated utility—post-ADC, in low/heterogeneous expressors, or via superior tolerability and operational simplicity—to justify late-stage investment.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
